TrilliumBiO and Oncobit Join Forces to Advance Uveal Melanoma Monitoring in the U.S.

TrilliumBiO and Oncobit Collaboration: Enhancing Uveal Melanoma Care in the U.S.

On December 9, 2025, TrilliumBiO, a pioneer in biomarker discovery and precision diagnostics, announced an exciting partnership with Oncobit, a leading Swiss company dedicated to precision oncology. This collaboration aims to provide innovative monitoring solutions for uveal melanoma patients across the United States, significantly addressing the needs of this underserved patient demographic.

Bridging the Gap in Uveal Melanoma Care

Uveal melanoma, while rare, is the most common primary eye cancer in adults, and its management is critical for improving patient outcomes. This partnership focuses on integrating diagnostic insights with cutting-edge therapies, allowing healthcare professionals to make more informed treatment decisions. By leveraging Oncobit's proprietary technologies, TrilliumBiO aims to deliver comprehensive, personalized care to patients suffering from this concerning condition.

The two companies plan to develop and launch Oncobit's uveal melanoma solution in TrilliumBiO's multi-accredited laboratory. This will ensure that healthcare providers nationwide can access these innovative monitoring tools. The collaboration involves the implementation of Oncobit’s Personalized Monitoring (PM) platform alongside advanced software for data interpretation, focusing on changes in circulating tumor DNA (ctDNA). Studies have indicated that ctDNA dynamics tracked with Oncobit’s PM can effectively predict patient response to treatment and disease progression, establishing its value in the clinical management of metastatic uveal melanoma.

Empowering Patients and Physicians

Laura Vivian, CEO of TrilliumBiO, expressed her enthusiasm about the partnership, emphasizing the company's commitment to improve diagnostics in rare diseases. She stated, "By combining advanced diagnostics with monitoring solutions, we're empowering patients and their families by providing clearer insights and informed decision-making capabilities throughout their treatment journey."

The initiative is designed to offer a dual benefit: a deeper understanding of the disease for patients and a reliable tool for physicians to optimize treatment strategies based on molecular residual disease (MRD) information. Oncobit's Dr. Claudia Scheckel noted that expanding access to next-generation diagnostics for uveal melanoma will greatly assist patients and families as they navigate the complexities of care while paving the way for potential new biomarkers and indications in precision oncology.

TrilliumBiO: A Leader in Diagnostic Innovation

TrilliumBiO is recognized for its efforts to translate clinical findings into market-ready diagnostic solutions. Their expertise in developing and commercializing unique diagnostic tests has made them an authority in the field. The company focuses on addressing intricate medical challenges with validated, physician-guided diagnostics. This partnership with Oncobit reinforces their role as a leader in advancing healthcare outcomes for patients with serious conditions.

Oncobit: Pioneering Cancer Monitoring Technologies

Oncobit has established itself as a premier player in the oncology space with a unique data-driven cancer monitoring platform that qualitatively and quantitatively detects cancer markers in liquid biopsies. By employing innovative technology, Oncobit's tools enable real-time monitoring and help tailor therapy management to individual patient needs. Their solutions are already trusted by numerous pharmaceutical firms and clinical laboratories, demonstrating the high demand for advanced cancer analytics.

In conclusion, the collaboration between TrilliumBiO and Oncobit heralds a new era of monitoring for uveal melanoma, improving patient management, and fostering personalized treatment options. As both firms continue to work together, they pave the way for advancements in how practitioners can manage rare cancers effectively, ultimately saving lives and enhancing quality of care for patients across the United States.